Risk of Esophageal Cancer Decreases With Height, According to New Study.

Taller individuals are less likely to develop esophageal cancer [adenocarinoma] and it’s precursor, Barrett’s esophagus, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

Esophageal cancer is the fastest growing cancer in the United States, with over a 600% increase in the past decades.  

Esophageal cancer is also one of the most deadly of cancers, with an overall 5 year survival rate of only 17.5%.  There are no standard or routine screenings to detect esophageal cancer in its earliest stages and symptoms often arise once the cancer has spread.  Esophageal cancer is often diagnosed in later stages reflecting on the fact that Stage IV esophageal cancer has a survival rate of only 3.8%.  With no known risk factors, research such as this is imperative to finding clues as to what causes this lethal disease.

Taller individuals are less likely to develop esophageal cancer [adenocarinoma] and it’s precursor, Barrett’s esophagus, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.“Individuals in the lowest quartile of height (under 5’7″ for men and 5’2″ for women) were roughly twice as likely as individuals in the highest quartile of height (taller than 6′ for men and 5’5″ for women) to have Barrett’s esophagus or esophageal cancer,” said Aaron P. Thrift, PhD, lead study author from the Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

“Interestingly, the relationship between height and esophageal cancer is opposite from many other cancers — including colorectal, prostate and breast — where greater height is associated with an increased risk.”

Researchers conducted a large pooled analysis using data from 14 population-based epidemiologic studies within the International Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON), including 1,000 cases of esophageal cancer and twice as many cases of Barrett’s esophagus, and twice as many controls.

The researchers conducted multiple analyses, including using Mendelian randomization (which incorporates genetic information with traditional approaches) to overcome issues of confounding and bias. The results from all analyses consistently demonstrated an inverse association between height and Barrett’s esophagus or esophageal cancer. There were no differences in these estimates based on sex, age, education, smoking, GERD symptoms or body mass index. Adjusting for abdominal obesity yielded similar results.

“The identification of risk factors, such as height, will allow us to create more sophisticated and accurate methods to quantify patient risk, which will hopefully be used in the future to decide who should undergo endoscopic screening for these conditions,” added Dr. Thrift.

The researchers report no obvious explanation for the association between short height and Barrett’s esophagus or esophageal cancer. Future studies investigating the potential causal mechanisms by which risk for Barrett’s esophagus or esophageal cancer might be influenced by height are justified.

Esophageal cancer incidence increased eight-fold in the U.S. from 1973 to 2008. Almost all cases arise from Barrett’s esophagus. Learn more about the management of Barrett’s esophagus in the American Gastroenterological Association medical position statement.

Source:
American Gastroenterological Association  1 Thrift, A. P., Risk of Esophageal Adenocarcinoma Decreases With Height, Based on Consortium Analysis and Confirmed by Mendelian Randomization. Clinical Gastroenterology and Hepatology 2014: 12(10): 1667-1676.e1 
Advertisements

Comments are closed.

%d bloggers like this: